loading
Clearmind Medicine Inc stock is traded at $1.02, with a volume of 77,265. It is up +4.08% in the last 24 hours and down -5.56% over the past month. Clearmind Medicine Inc is a psychedelic pharmaceutical biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and underserved health problems, including alcohol use disorder. Its primary objective is to research and develop psychedelic-based compounds and attempt to commercialize them as regulated medicines, foods, or supplements. The company's intellectual portfolio currently consists of four patent families. The company intends to seek additional patents for its compounds whenever warranted and will remain opportunistic regarding the acquisition of additional intellectual property to build its portfolio.
See More
Previous Close:
$0.98
Open:
$1
24h Volume:
77,265
Relative Volume:
0.35
Market Cap:
$5.39M
Revenue:
-
Net Income/Loss:
$-6.78M
P/E Ratio:
-0.0239
EPS:
-42.6996
Net Cash Flow:
$-4.67M
1W Performance:
-8.93%
1M Performance:
-5.56%
6M Performance:
-30.14%
1Y Performance:
-15.00%
1-Day Range:
Value
$0.952
$1.02
1-Week Range:
Value
$0.95
$1.09
52-Week Range:
Value
$0.85
$2.30

Clearmind Medicine Inc Stock (CMND) Company Profile

Name
Name
Clearmind Medicine Inc
Name
Phone
-
Name
Address
-
Name
Employee
1
Name
Twitter
Name
Next Earnings Date
Name
Latest SEC Filings
Name
CMND's Discussions on Twitter

Compare CMND with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
CMND
Clearmind Medicine Inc
1.02 5.39M 0 -6.78M -4.67M -42.70
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
493.84 122.76B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
602.64 61.38B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
614.76 36.37B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
251.56 30.12B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
244.90 24.70B 3.81B -644.79M -669.77M -6.24

Clearmind Medicine Inc Stock (CMND) Latest News

pulisher
Apr 25, 2025

Clearmind Medicine files patent for eating disorder treatment - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

SciSparc and Clearmind file patent for eating disorder treatment - Investing.com

Apr 25, 2025
pulisher
Apr 25, 2025

Clearmind Medicine files patent for eating disorder treatment By Investing.com - Investing.com South Africa

Apr 25, 2025
pulisher
Apr 25, 2025

SciSparc and Clearmind file patent for eating disorder treatment By Investing.com - Investing.com India

Apr 25, 2025
pulisher
Apr 25, 2025

Psychedelic: Clearmind completes clinical site initiations for AUD trial - Yahoo Finance

Apr 25, 2025
pulisher
Apr 25, 2025

SciSparc-Clearmind Collaboration Leads to Filing of - GlobeNewswire

Apr 25, 2025
pulisher
Apr 25, 2025

Clearmind Medicine Inc. Files International Patent for Novel Treatment of Eating Disorders Using 3-MMC and PEA - Nasdaq

Apr 25, 2025
pulisher
Apr 25, 2025

Novel Eating Disorder Treatment Patent Filed for 70M Patient Market | SPRC Stock News - Stock Titan

Apr 25, 2025
pulisher
Apr 25, 2025

Clearmind Medicine Files International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders - TradingView

Apr 25, 2025
pulisher
Apr 23, 2025

Clearmind Medicine Completes the Initiation of its Alcohol Use Disorder Phase I/IIa Clinical Trial at all Current Clinical Sites - The Manila Times

Apr 23, 2025
pulisher
Apr 23, 2025

Clearmind Medicine Inc. Initiates Patient Enrollment for Phase I/IIa Clinical Trial in Alcohol Use Disorder - Nasdaq

Apr 23, 2025
pulisher
Apr 23, 2025

Clearmind Medicine (NASDAQ:CMND) Stock Price Down 4.8% – Here’s Why - Defense World

Apr 23, 2025
pulisher
Apr 22, 2025

Clearmind Medicine Inc (CMND) requires closer examination - uspostnews.com

Apr 22, 2025
pulisher
Apr 21, 2025

Clearmind Medicine Inc Inc. (CMND) Price Performance and Its Relation to the Tech Industry - investchronicle.com

Apr 21, 2025
pulisher
Apr 21, 2025

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts - TradingView

Apr 21, 2025
pulisher
Apr 21, 2025

Clearmind Medicine to Host Live Webinar 'Gazing Through the Crystal Ball” Featuring Leading Psychedelic Experts - The Manila Times

Apr 21, 2025
pulisher
Apr 21, 2025

Clearmind Medicine to Host Live Webinar “Gazing Through the Crystal Ball” Featuring Leading - Bluefield Daily Telegraph

Apr 21, 2025
pulisher
Apr 17, 2025

Clearmind Medicine Receives Notice Of Allowance For United States Patent Covering Binge Behavior - marketscreener.com

Apr 17, 2025
pulisher
Apr 17, 2025

Clearmind Medicine Receives Notice of Allowance for United States Patent Covering Binge Behavior - TradingView

Apr 17, 2025
pulisher
Apr 16, 2025

Clearmind Medicine Launches First U.S. Clinical Site For FDA-Approved Alcohol Use Disorder Trial - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

Clearmind Medicine begins phase I/IIa trial for AUD treatment - Investing.com

Apr 16, 2025
pulisher
Apr 16, 2025

Clearmind Medicine Launches First U.S. Clinical Site for its FDA-Approved Clinical Trial to Combat Alcoholism - The Manila Times

Apr 16, 2025
pulisher
Apr 16, 2025

Clearmind Medicine Inc. Initiates Phase I/IIa Clinical Trial for CMND-100 in Alcohol Use Disorder at Johns Hopkins University - Nasdaq

Apr 16, 2025
pulisher
Apr 16, 2025

Clearmind Medicine Launches First U.S. Clinical Site For Its FDA-Approved Clinical Trial To Combat Alcoholism - MarketScreener

Apr 16, 2025
pulisher
Apr 11, 2025

Psychedelic: Clearmind initiates U.S. clinical site for CMND-100 trial - Yahoo Finance

Apr 11, 2025
pulisher
Apr 11, 2025

Clearmind Medicine (CMND) Launches U.S. Clinical Trial for Alcoh - GuruFocus

Apr 11, 2025
pulisher
Apr 10, 2025

Clearmind Medicine Announces First U.S. Clinical Site Initiation for CMND-100 Clinical Trial in Patients with Alcohol Use Disorder - The Manila Times

Apr 10, 2025
pulisher
Apr 08, 2025

Clearmind Medicine files patent for new psychedelic compounds - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Clearmind Medicine Announces the Publication of International Patent Application for Next-Gen Psychedelic Compounds to Treat Mental Health Disorders - The Manila Times

Apr 08, 2025
pulisher
Apr 07, 2025

Clearmind Medicine stock hits 52-week low at $0.95 By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Clearmind Medicine stock hits 52-week low at $0.95 - Investing.com Australia

Apr 07, 2025
pulisher
Apr 01, 2025

Clearmind launches data system for alcohol addiction trial - Investing.com

Apr 01, 2025
pulisher
Apr 01, 2025

Clearmind Implements EDC System To Streamline Phase I/II Trial For Alcohol Use Disorder Drug - Nasdaq

Apr 01, 2025
pulisher
Apr 01, 2025

Clearmind Medicine launches EDC system to support Phase I/II trial - TipRanks

Apr 01, 2025
pulisher
Apr 01, 2025

Clearmind launches data system for alcohol addiction trial By Investing.com - Investing.com Australia

Apr 01, 2025
pulisher
Apr 01, 2025

Clearmind Launches its EDC System to Support its Phase I/II Clinical Trial of its MEAI-Based Treatment - The Manila Times

Apr 01, 2025
pulisher
Mar 22, 2025

Psychedelic Revolution: Inside Clearmind Medicine's Breakthrough - AInvest

Mar 22, 2025
pulisher
Mar 22, 2025

Psychedelic: Exclusive talk with biotech company Clearmind Medicine - Yahoo Finance

Mar 22, 2025
pulisher
Mar 21, 2025

Clearmind’s AUD drug candidate arrives in the U.S. for trials By Investing.com - Investing.com South Africa

Mar 21, 2025
pulisher
Mar 21, 2025

Clearmind Medicine Moves Closer to CMND-100 Trial After Alcohol Use Disorder Drug Candidate Arrives in US - MarketScreener

Mar 21, 2025
pulisher
Mar 21, 2025

Clearmind’s AUD drug candidate arrives in the U.S. for trials - Investing.com

Mar 21, 2025
pulisher
Mar 21, 2025

Clearmind Medicine's FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - The Manila Times

Mar 21, 2025
pulisher
Mar 21, 2025

Clearmind Medicine Inc. Announces Arrival of CMND-100 in the U.S. Ahead of Phase I/IIa Trial for Alcohol Use Disorder - Nasdaq

Mar 21, 2025
pulisher
Mar 21, 2025

Clearmind Medicine’s FDA-Approved Clinical Trial for CMND-100 Moves Forward as Drug Arrives in the U.S., Advancing Toward Key Milestones - TradingView

Mar 21, 2025
pulisher
Mar 19, 2025

Clearmind and Polyrizon partner on nasal drug delivery By Investing.com - Investing.com South Africa

Mar 19, 2025
pulisher
Mar 19, 2025

Clearmind Medicine To Develop Novel Intranasal Formulation With Polyrizon - Nasdaq

Mar 19, 2025
pulisher
Mar 19, 2025

Clearmind and Polyrizon partner on nasal drug delivery - Investing.com

Mar 19, 2025
pulisher
Mar 19, 2025

Clearmind to Evaluate Intranasal Delivery of Its Psychedelic Drug Combination - The Manila Times

Mar 19, 2025
pulisher
Mar 19, 2025

Clearmind begins phase I/IIa trial for AUD treatment - Investing.com Australia

Mar 19, 2025
pulisher
Mar 18, 2025

Clearmind Medicine Advances CMND-100 To Clinical Trials For Alcohol Use Disorder - Nasdaq

Mar 18, 2025
pulisher
Mar 18, 2025

Clearmind Medicine Initiates First Clinical Trial Of CMND-100 For Alcohol Use Disorder Treatment - Nasdaq

Mar 18, 2025

Clearmind Medicine Inc Stock (CMND) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.59
price up icon 0.24%
$69.69
price up icon 1.06%
$32.20
price up icon 0.53%
$23.46
price down icon 36.06%
$102.02
price down icon 15.36%
biotechnology ONC
$244.90
price down icon 4.40%
Cap:     |  Volume (24h):